ProMis Neurosciences’ shares fell after Acumen Pharmaceuticals disclosed that its Alzheimer’s therapy targeting a similar amyloid mechanism did not slow cognitive or functional decline versus placebo in a mid-stage study. The report framed the market reaction as potentially disproportionate, with ProMis’ CEO characterizing investor assumptions about mechanistic failure as not necessarily justified. The episode highlights how single readouts can rapidly reprice risk across mechanistically overlapping Alzheimer’s programs, even before confirmatory data from each company’s own trials. It also underscores the sensitivity of amyloid-targeting strategies to endpoints, study design, and patient selection. For biotech stakeholders, the situation is a reminder that competitive signal interpretation can become a dominant near-term driver of capital allocation—particularly in crowded late-stage or mid-stage neurodegeneration spaces.